Phio Pharmaceuticals Corp <PHIO.OQ> expected to post a loss of 36 cents a share - Earnings Preview
Phio Pharmaceuticals Corp PHIO.OQ PHIO.O is expected to report resultson August 12 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Phio Pharmaceuticals Corp is for a loss of 36 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for Phio Pharmaceuticals Corp is $14.00, about 83.9% above its last closing price of $2.25
This summary was machine generated August 8 at 14:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Investing in Robotics & Automation
Robotics and automation are a structural megatrend driven by labor shortages, supply chain shifts, and the push for efficiency.The investment landscape spans industrial leaders, healthcare innovators, logistics adopters, and semiconductor enablers.
Investing in Artificial General Intelligence (AGI)
AGI promises transformative productivity and economic gains but carries unprecedented technical, ethical, and social risks.Significant exposure comes through tech giants, semiconductor leaders, and cloud infrastructure providers, fueling AGI research.
September Global Central Bank Divergence: How Will U.S. Stocks and Forex Markets Move?
TradingKey - Despite the divergence in monetary policies among major global central banks in September (with the Federal Reserve cutting rates while the European Central Bank, Bank of England, and Bank of Japan maintain steady rates), we expect the policy directions of the Fed, ECB, and BoE to...
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.
